• Valink Therapeutics

  Participated · Series A · Oct 2025

  Valink Therapeutics engineers next-generation oncology therapeutics that combine bispecific antibody technology with antibody-drug conjugates to improve efficacy, safety, and precision. Its proprietary discovery platform and V-gate™ approach expand the design space for bsADCs, enabling fine-tuned target control and an improved therapeutic index compared with current ADC technologies. Beyond bsADCs, the company is building a suite of multispecific or multifunctional ADCs and multivalent agonists to address additional therapeutic needs. Valink is advancing two first-in-class oncology programs for solid tumors, including colorectal cancer, which are now moving toward preclinical development. Proceeds from recent financing will fund this pipeline progression and further platform development. The company operates from its headquarters in Cambridge, Massachusetts, with R&D facilities in the United Kingdom.

• Calluna Pharma

  Participated · Series A · Jan 2024

  Calluna Pharma was formed by the merger of Oxitope Pharma and Arxx Therapeutics and pursues therapies that harness the innate immune system by precision targeting of upstream innate immune amplifiers (DAMPs). The company has built a pipeline of selective antibodies addressing acute and chronic inflammation and non-resolving tissue fibrosis, claiming favorable safety profiles and broad downstream pathway disruption. Calluna has four programs, including lead clinical-stage CAL101, a monoclonal antibody that neutralizes S100A4, and CAL102, an antibody against oxidized phospholipids that showed efficacy in several preclinical models. The company says its candidates address unmet clinical needs across indications such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, rheumatoid arthritis, and severe steroid-insensitive asthma. Calluna plans to advance its pipeline toward multiple key clinical milestones and is raising further financing to support development over the next 2.5 years.

• Teitur Trophics

  Participated · Series A · Mar 2023

  Teitur Trophics develops circular peptides intended to treat neurodegenerative disorders where there are currently no therapies. Its lead candidate, TT-P34, is designed to clear toxic protein deposits, restore mitochondrial function in affected brain cells and promote pro-survival signaling. The company plans to advance TT-P34 from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases. Teitur was founded by Simon Molgaard, Anders Dalby, Mathias Ollendorff and Simon Glerup. The company recently completed a financing round to support these development plans. It is based in Aarhus, Denmark.

No current team members are available.